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Future analyses of my study cohort can hopefully
provide more data on the association between local and
systemic inflammation and cardiac comorbidities in
COPD.
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Background: Numerous studies have demonstrated
evidence of oxidative stress in COPD, in both respiratory
tract lining fluids and biopsies. Antioxidant response in
airway inflammatory cells to a pro-oxidative
environment is however poorly understood. We have
previously demonstrated an enhanced antioxidant
enzyme activity in macrophages from asthmatics. This
study was performed to assess whether a similar adap-
tation in intra-cellular antioxidants occurred in subjects
with COPD. The activities of enzymatic antioxidants
were examined in alveolar mixed cell populations and
compared to healthy age-matched controls (ACs) and
young adults, to permit the relative contributions of
disease state and natural ageing to be disentangled.
Methods: Airway leukocytes were obtained by bronchos-
copy-based lavage and cellular activities of Cu,Zn
superoxide dismutase (SOD1), glutathione peroxidase
(GPx), catalase (CAT) and glutathione reductase (GSSG-
red) were determined. In addition, cellular glutathione
and glutathione disulphide concentrations were
quantified to determine cellular redox status.
Results: No differences in the activity of the major
enzymatic antioxidants or intra-cellular GSH concen-
tration were observed between COPD patients and ACs.
In contrast, significantly reduced SOD1 (p<0.001), GPx
(p=0.04) and GSSG-red (p=0.01) activities were
observed in the ACs relative to the young adult group. In
contrast, catalase activity was elevated in the ACs
(p=0.001), but again with no further enhancement in
the COPD group.
Conclusion: These data demonstrate a loss of adaptive
plasticity associated with ageing, rather than a COPD-
specific down regulation of antioxidant defences. These
data do however highlight that in COPD, unlike asthma,
the imposition of oxidative stress does not induce
protective adaptations, implying a greater sensitivity to
oxidant injury in vivo.
Neurotrophins in COPD
C. Dagnell1, M. Mikko1, M. Löfdahl1, E. Roos-Engstrand2,
A. Blomberg2, M. Sköld1 and C.O. Höglund1,3
1Department of Medicine Solna, Respiratory Medicine
Unit, Karolinska Institutet and Karolinska University
Hospital Solna, Stockholm, Sweden
2Department of Respiratory Medicine and Allergy,
University Hospital, Umeå, Sweden
3Department of Physiology and Pharmacology,
Karolinska Institutet, Stockholm, Sweden
E-mail address: charlotta.dagnell@ki.se
Nerve growth factor (NGF) and neurotrophin-3 (NT-3)
belong to the neurotrophin family and are important
growth- and survival factors for neurons. Lately, they
have also been shown to be potent inflammatory
mediators as well as factors promoting tissue repair
processes. Increased levels of neurotrophins have
previously been shown in the airways of patients with
asthma and sarcoidosis.
In this study we investigated the levels of neuro-
trophins in the airways of patients with moderate to
severe COPD (n=25), healthy non-smokers (n=12) and
asymptomatic smokers (n=16). We found decreased
levels of NGF and NT-3 in bronchoalveolar lavage fluid
(BALF) in COPD patients and asymptomatic smokers as
compared to healthy non-smokers. These findings
suggest that smoking per se decreases the release of
neurotrophins in the airways. Structural cells, such as
epithelial cells and fibroblasts, are known sources of
neurotrophins. We found that NGF secretion was
decreased from cultured human lung fibroblasts
exposed to cigarette smoke extract.
These results indicate that smoking have inhibitory
effects on neurotrophin secretion in the airways. The
functional consequence of lower levels of neurotrophins
in the airways of smokers and COPD patients is still
unknown and further studies are required to elucidate
the role of neurotrophins in inflammatory pulmonary
diseases.
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Chronic airway inflammation is a key feature in the
pathogenesis of COPD, and inhaled corticosteroids (ICS)
are widely used to alleviate airway inflammation in
COPD. We tested if non-invasive markers of airway
inflammation are related to lung function in COPD, or if
these markers can predict responsiveness to ICS.
S4 M. Sköld et al.
We measured alveolar NO concentration, bronchial
NO flux, and levels of 8-isoprostane and LTB4 in exhaled
breath condensate (EBC) in 61 subjects with COPD.
These measurements were repeated in 40 patients after
4 weeks of treatment with inhaled fluticasone (500 μg
b.i.d.).
Subjects with COPD had higher levels of 8-iso-
prostane and LTB4 in EBC, increased alveolar NO
concentration, but decreased bronchial NO flux as
compared with healthy subjects. Bronchial NO flux
correlated positively with β2-agonist-induced change in
FEV1 (r=0.372, p=0.003), but other inflammatory
markers were not related to lung function. Baseline
levels of bronchial NO flux were associated with higher
increase in FEV1/FVC (r=0.313, p=0.049) and better
symptom alleviation during the fluticasone treatment.
In conclusion, high bronchial NO flux in COPD predicts
favourable acute response to β2-agonists and a good
response also to treatment with ICS. The other tested
markers are not related to disease severity or treatment
responses in COPD.
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Vascular endothelial growth factor (VEGF) is involved in
lung development, angiogenesis and in response to
injury. Chronic obstructive pulmonary disease (COPD) is
an inflammatory disease characterised by accumulation
of T-cells and remodelling of the airways. We
hypothesized that T-cell secreted VEGF is modulated by
cigarette-smoke and by a hypoxic microenvironment
and that these conditions have an impact on protein
secretion from T-cells from patients with COPD.
T-cells were isolated from peripheral blood of
healthy donors and stimulated in normoxia and hypoxia
with or without exposure to cigarette smoke extract
(CE). VEGF and selected cytokines were measured in
T-cell conditioned media (CBA flex set and ELISA).
Hypoxia (1-2% O2) stimulated VEGF secretion from T-
cells, whereas the release of inflammatory cytokines
(IL-4, IL-6, IL-10, IL-13, IFN-γ and TNF) were not
affected. CE did not influence VEGF secretion neither in
hypoxia nor in normoxia whereas cytokine secretion was
inhibited by CE in both conditions. T-cells from COPD-
patients (FEV1 23-63 % of predicted) secreted
significantly more VEGF compared to T-cells from age-
matched healthy individuals.
The persistent VEGF secretion despite an inhibition
of other T-cell secreted mediators by CE suggests that
VEGF may act as a modulating factor in a hypoxic
microenvironment in COPD. This hypothesis is supported
by elevated VEGF levels from stimulated T-cells from
COPD patients.
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Type I and III collagen protein precursors are increased
in fibrosing processes in the lung. The aim of this study
was to compare the expression of these precursor
proteins in the small airways of nonsmokers, smokers
and COPD-patients with different severity of the
disease, as a marker of newly formed fibrosis.
Procollagen I and III aminoterminal peptides (PINP
and PIIINP) were studied by immunohistochemistry in
lung tissue of 16 life-long non-smokers, 20 current
smokers with normal lung function and 20 current
smokers with COPD. Tissue specimens from tumor-free
peripheral lung tissue were selected. COPD was defined
according to GOLD criteria.
No expression of PINP was found in the subepithelial
layer of small bronchioli. In peripheral bronchioli the
PIIINP expressing layer was thickest in stage I-II COPD
and thinnest in severe COPD (p=0.015). Western blotting
of the total lung homogenates showed a higher level of
PIIINP in nonsmokers compared to smoker groups.
In small airways, PIIINP expression increases in mild-
moderate COPD but decreases at end-state disease, as a
marker of cessation of active fibrogenesis. However, the
total lung homogenate shows decreased expression of
PIIINP in all smoker groups, referring to the possibility of
balance shift towards degradation in other lung
compartments.
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Is COPD a risk factor for increased arterial stiffness?
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